WntResearch’s CEO: “In a better position than ever”

Reporting its third quarter, WntResearch is focusing on the restart of the NeoFox study with Foxy-5. The first patient was recently enrolled in the redesigned study, where the next milestone will be a first readout when half of the patients have been treated. BioStock reached out to CEO Pernilla Sandwall to get her thoughts on the development during the quarter.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/11/wntresearchs-ceo-in-a-better-position-than-ever/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se